NCT05024851

Brief Summary

Scientific research on pruritus is in intensive development, with significant advances in understanding its pathophysiology. The causes of pruritus are very huge; they can be classified into different categories; we can find dermatological causes, systemic causes, neuropathic or neurological causes, psychogenic or even idiopathic causes. The diagnosis of psychogenic pruritus is often over stated, when no cause is found; therefore, it is important to see what is really relieving from psychic so as not to over-diagnose and adopt a therapy more in line with the real problem of the patient. In daily practice, it seems to have a tendency to separate psychogenic and neurogenic etiologies in the diagnosis of neuropathic or psychogenic pruritus. In the case of patients with psychogenic pruritus and neuropathic pruritus, no study has attempted to study the respective part of psychogenic and neurogenic components. Consequently, it would therefore be interesting to assess the areas of superposition and distinction of neuropathic and psychogenic pruritus. The aim of this pilot study is to assess the psychogenic and neurogenic components of psychogenic pruritus and neuropathic pruritus in order to improve understanding of the mechanism and therefore their management. The main objective of this study is to highlight the differences and the potential common characteristics between psychogenic and neuropathic pruritus in order to improve the differential diagnosis between these two pathologies. The secondary objective of this study is to describe the psychogenic and neurogenic characteristics of psychogenic and neuropathic pruritus.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

August 25, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 27, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 8, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2022

Completed
Last Updated

January 12, 2024

Status Verified

January 1, 2024

Enrollment Period

11 months

First QC Date

August 23, 2021

Last Update Submit

January 10, 2024

Conditions

Keywords

Psychogenic PruritusNeuropathic PruritusPsychogenic ComponentNeurogenic Component

Outcome Measures

Primary Outcomes (6)

  • Questionnaire de Brest

    Qualitative assessment of pruritus, specifying the chronology, location, intensity, characteristics and effect on daily activities of the itching induced by pruritus

    at the enrollment

  • HADS (Hospital Anxiety and Depression Scale)

    Total score for Depression or Anxiety 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)

    at the enrollment

  • NP5

    A score of two criteria out of five is optimal to discriminate Neuropathic pruritus (NP) from Non-NP

    at the enrollment

  • TAS-20

    The TAS-20 is a self-report scale that is comprised of 20 items. Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree. There are 5 items that are negatively keyed (items 4, 5, 10, 18 and 19). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

    at the enrollment

  • DN4i

    score equal to or greater than 3 : in favor of neuropathic pruritus

    at the enrollment

  • Diagnosis criteria of functional itch disorder or psychogenic pruritus, from the French psychodermatology group

    three compulsory criteria; Three additional criteria from seven items should also be present

    at the enrollment

Study Arms (2)

Patients with Psychogenic pruritus

Other: Questionnaires

Patients with Neuropathic Pruritus

Other: Questionnaires

Interventions

Evaluation of the Psychogenic and Neurogenic Components using questionnaires

Patients with Neuropathic PruritusPatients with Psychogenic pruritus

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with neuropathic or psychogenic pruritus consulting in the dermatology department of the CHRU de Brest.

You may qualify if:

  • Major (\> 18 years old)
  • Diagnosis of psychogenic pruritus or neuropathic pruritus made in consultation, in day hospital or in hospital, within the dermatology department at the CHRU de Brest
  • Able to understand and agree to sign the information and non-opposition notice
  • No opposition of the patient

You may not qualify if:

  • Patient under legal protection (guardianship, curatorship)
  • Minor (\<18 years old)
  • Acute or chronic condition which could limit the patient's ability to the study's participation
  • Inability to understand and sign the information and non-opposition notice
  • Refusal to give no opposition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHRU de Brest

Brest, 29609, France

Location

MeSH Terms

Conditions

PruritusNeuralgia

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue DiseasesSkin ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic Manifestations

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2021

First Posted

August 27, 2021

Study Start

August 25, 2021

Primary Completion

July 8, 2022

Study Completion

July 8, 2022

Last Updated

January 12, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will share

All collected data that underlie results in a publication

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available beginning two years and ending five years following the publication
Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

Locations